LDDD logo

Longduoduo Company Limited (LDDD) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Longduoduo Company Limited (LDDD) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 15 mar 2026
Puntuación de IA de 51/100

Longduoduo Company Limited (LDDD) Resumen de Asistencia Médica y Tuberías

CEOHongxiao Zhou
Empleados52
Sede CentralHohhot, CN
Año de la oferta pública inicial (OPI)2023

Longduoduo Company Limited delivers preventive healthcare solutions in China, addressing cardiovascular and cerebrovascular diseases. Their services encompass disease screening, treatments, and healthcare products distributed via third-party channels. Operating in the diagnostics and research segment, the company caters to a growing demand for preventive care in the Chinese market.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 15 mar 2026

Tesis de Inversión

Longduoduo Company Limited presents a speculative investment opportunity within the Chinese preventive healthcare market. The company's focus on cardiovascular and cerebrovascular disease prevention aligns with growing health concerns and government support for proactive healthcare measures. However, the company's negative P/E ratio of -51.82 and negative profit margin of -10.9% indicate financial challenges. The high gross margin of 98.5% suggests potential for profitability if operational efficiencies improve. Key growth catalysts include expanding service offerings and penetrating new geographic regions within China. Investors should carefully consider the risks associated with investing in a small-cap OTC-listed company with limited financial history.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth but also higher risk.
  • Negative P/E ratio of -51.82 reflects current unprofitability, requiring careful monitoring of future earnings.
  • High gross margin of 98.5% suggests strong pricing power or a focus on high-value services.
  • Beta of 1.53 indicates higher volatility compared to the overall market.
  • No dividend yield reflects a focus on reinvesting earnings for growth.

Competidores y Pares

Fortalezas

  • Specialized focus on cardiovascular and cerebrovascular disease prevention.
  • Comprehensive range of preventive healthcare services and products.
  • Established network of third-party healthcare providers and sales agents.
  • Innovative treatment offerings such as meridian-regulating iatrotechnics.

Debilidades

  • Limited operating history as the company was founded in 2020.
  • Negative P/E ratio and profit margin indicate financial challenges.
  • Small market capitalization and OTC listing increase investment risk.
  • Dependence on third-party providers and sales agents.

Catalizadores

  • Upcoming: Potential partnerships with hospitals and clinics to expand service reach.
  • Ongoing: Expansion of service offerings to include new preventive healthcare treatments.
  • Ongoing: Development and launch of new healthcare products.
  • Ongoing: Leveraging telemedicine and digital health platforms to improve patient engagement.

Riesgos

  • Potential: Intense competition from established healthcare providers in China.
  • Potential: Changes in government regulations and healthcare policies could impact the company's operations.
  • Potential: Economic slowdown in China could reduce demand for preventive healthcare services.
  • Ongoing: Limited financial disclosure increases investment risk.
  • Ongoing: Low trading volume and liquidity can lead to price volatility.

Oportunidades de crecimiento

  • Expansion into New Geographic Regions: Longduoduo can expand its services to other regions within China, targeting areas with high prevalence of cardiovascular and cerebrovascular diseases. The Chinese healthcare market is vast, offering significant growth potential for companies that can effectively penetrate new regions. This expansion could involve establishing new partnerships with local healthcare providers and sales agents. Timeline: Ongoing.
  • Development of New Preventive Healthcare Products: Longduoduo can invest in research and development to create new preventive healthcare products that complement its existing service offerings. These products could include dietary supplements, medical devices, or digital health solutions. The market for preventive healthcare products is growing rapidly, driven by increasing consumer awareness and demand for proactive health management. Timeline: Ongoing.
  • Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Longduoduo with access to a wider patient base and enhance its credibility. These partnerships can involve offering Longduoduo's services within the hospital or clinic setting, or co-developing new preventive healthcare programs. The hospital and clinic market in China is large and fragmented, offering numerous partnership opportunities. Timeline: Ongoing.
  • Leveraging Telemedicine and Digital Health Platforms: Longduoduo can leverage telemedicine and digital health platforms to expand its reach and improve patient engagement. This can involve offering online consultations, remote monitoring, and personalized health coaching. The digital health market in China is growing rapidly, driven by increasing internet penetration and the adoption of mobile health technologies. Timeline: Ongoing.
  • Focus on Personalized Healthcare Solutions: Tailoring preventive healthcare solutions to individual patient needs can improve outcomes and enhance patient satisfaction. This can involve using genetic testing, lifestyle assessments, and other data to develop personalized treatment plans. The market for personalized healthcare is growing, driven by advances in genomics and data analytics. Timeline: Ongoing.

Oportunidades

  • Expansion into new geographic regions within China.
  • Development of new preventive healthcare products and services.
  • Strategic partnerships with hospitals and clinics.
  • Leveraging telemedicine and digital health platforms.

Amenazas

  • Intense competition from established healthcare providers.
  • Changes in government regulations and healthcare policies.
  • Economic slowdown in China.
  • Potential for product liability claims.

Ventajas competitivas

  • Specialized treatment offerings like meridian-regulating iatrotechnics and double blood purification.
  • Focus on the specific market of cardiovascular and cerebrovascular disease prevention in China.
  • Established network of third-party healthcare service providers and sales agents.
  • Proprietary healthcare products and treatment protocols.

Acerca de LDDD

Founded in 2020 and headquartered in Hohhot, China, Longduoduo Company Limited operates within the preventive healthcare sector, focusing on solutions for cardiovascular and cerebrovascular diseases. The company's inception was driven by the increasing prevalence of these conditions in China and the growing demand for proactive healthcare measures. Longduoduo offers a suite of preventive healthcare services, including disease screening, healthcare treatments, and healthcare products. These services are designed to mitigate the risks associated with myocardial infarction, cerebral infarction, hemiplegia, and other related conditions. The company utilizes a network of third-party healthcare service providers, product suppliers, and sales agents to deliver its offerings to the market. Longduoduo's service portfolio includes specialized treatments such as meridian-regulating and consciousness restoring iatrotechnics, double blood purification, immunological ozonated autohemotherapy, platelet-rich plasma, relaxation therapy, vegetative nerve regulation, and microwave therapy. These diverse therapeutic approaches aim to provide comprehensive preventive care to its clientele. While a relatively young company, Longduoduo is strategically positioned to capitalize on the expanding healthcare market in China, driven by increasing health awareness and government initiatives promoting preventive care.

Qué hacen

  • Provides disease screening services for early detection of health risks.
  • Offers healthcare treatments focused on preventing cardiovascular and cerebrovascular diseases.
  • Distributes healthcare products designed to promote overall wellness and disease prevention.
  • Delivers meridian-regulating and consciousness restoring iatrotechnics.
  • Offers double blood purification services.
  • Provides immunological ozonated autohemotherapy.
  • Administers platelet-rich plasma therapy.
  • Offers relaxation therapy, vegetative nerve regulation, and microwave therapy.

Modelo de Negocio

  • Generates revenue through the provision of preventive healthcare services.
  • Sells healthcare products through third-party distributors and sales agents.
  • Partners with healthcare providers to offer services within their facilities.
  • Focuses on preventing myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.

Contexto de la Industria

Longduoduo Company Limited operates in the growing Chinese healthcare market, specifically within the preventive healthcare segment. The demand for preventive care is increasing due to rising healthcare awareness and government initiatives promoting early disease detection and management. The market is competitive, with established players and emerging companies offering various preventive healthcare solutions. Longduoduo differentiates itself through its specialized treatments and focus on cardiovascular and cerebrovascular diseases. The company's success depends on its ability to effectively market its services, establish strong partnerships, and maintain high-quality standards.

Clientes Clave

  • Individuals seeking preventive healthcare solutions in China.
  • Patients at risk of cardiovascular and cerebrovascular diseases.
  • Healthcare providers who partner with Longduoduo to offer preventive services.
  • Consumers interested in purchasing healthcare products for disease prevention.
Confianza de la IA: 71% Actualizado: 15 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Longduoduo Company Limited (LDDD): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para LDDD.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para LDDD.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para LDDD.

MoonshotScore

51/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de LDDD en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Hongxiao Zhou

CEO

Hongxiao Zhou is the CEO of Longduoduo Company Limited, leading a team of 52 employees. His background includes experience in the healthcare sector, with a focus on preventive care and disease management. Prior to joining Longduoduo, Zhou held various leadership positions in healthcare companies, where he was responsible for developing and implementing strategic initiatives. He has a strong understanding of the Chinese healthcare market and the challenges and opportunities it presents. Zhou is committed to driving Longduoduo's growth and success by providing innovative and effective preventive healthcare solutions.

Historial: Since founding Longduoduo in 2020, Hongxiao Zhou has focused on establishing the company's presence in the Chinese preventive healthcare market. Key milestones under his leadership include developing a comprehensive range of preventive healthcare services and products, establishing a network of third-party healthcare providers and sales agents, and securing partnerships with key stakeholders in the healthcare industry. Zhou's strategic decisions have positioned Longduoduo for future growth and success.

Información del mercado OTC de LDDD

The OTC Other tier, also known as the Pink tier, represents the most speculative and least regulated segment of the OTC market. Companies in this tier often have limited financial disclosure, may be distressed, or may not meet the minimum requirements for higher OTC tiers like OTCQB or OTCQX. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. These companies may not be current in their reporting requirements.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for LDDD shares on the OTC market is likely to be limited, potentially resulting in wide bid-ask spreads and difficulty in executing large trades without significantly impacting the price. Low trading volume can exacerbate these issues, making it challenging for investors to enter or exit positions quickly. Investors should exercise caution and be aware of the potential for price volatility due to the illiquid nature of the stock.
Factores de riesgo OTC:
  • Limited financial disclosure increases the risk of investing in LDDD.
  • Low trading volume and liquidity can lead to price volatility.
  • OTC Other tier listing indicates a higher level of risk compared to stocks listed on major exchanges.
  • Potential for fraud or manipulation due to the lack of regulatory oversight.
  • Uncertainty regarding the company's long-term viability and financial stability.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal standing.
  • Attempt to obtain and review any available financial statements.
  • Assess the company's management team and their track record.
  • Research the company's industry and competitive landscape.
  • Understand the company's business model and revenue streams.
  • Evaluate the risks associated with investing in an OTC-listed company.
  • Consult with a financial advisor before making any investment decisions.
Señales de legitimidad:
  • Company has been in operation since 2020.
  • Focus on preventive healthcare solutions aligns with growing market demand.
  • Presence of a CEO and management team.
  • Company has 52 employees.

Preguntas Comunes Sobre LDDD

¿Cuáles son los factores clave para evaluar LDDD?

Longduoduo Company Limited (LDDD) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Specialized focus on cardiovascular and cerebrovascular disease prevention.. Riesgo principal a monitorear: Potential: Intense competition from established healthcare providers in China.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de LDDD?

LDDD actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de LDDD?

Los precios de LDDD se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre LDDD?

La cobertura de analistas para LDDD incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en LDDD?

Las categorías de riesgo para LDDD incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from established healthcare providers in China.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de LDDD?

La relación P/E para LDDD compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está LDDD sobrevalorada o infravalorada?

Determinar si Longduoduo Company Limited (LDDD) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de LDDD?

Longduoduo Company Limited (LDDD) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available company data and may be limited due to the company's OTC listing and disclosure status.
  • AI analysis pending for LDDD.
Fuentes de datos

Popular Stocks